Physician profile
Javier Bocanegra
NPI 1003837758
$9,393.76
in general payments reported to CMS, 2019-2025
36 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,286 · 2020: $1,680 · 2021: $814 · 2022: $431 · 2023: $1,263 · 2024: $1,685 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,182.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,765.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,564.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $772.76 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $719.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $613.87 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $480.80 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $423.52 | 2023-2025 | |
| Almatica Pharma LLC | $342.16 | 2023-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Allergan, INC. | $331.39 | 2019-2020 | |
| Abbvie INC. | $303.94 | 2020-2025 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.57 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Sanofi-Aventis U.S. LLC | $225.48 | 2019-2023 | |
| Pfizer INC. | $179.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.61 | 2021-2024 | Xifaxan |
| Eisai INC. | $149.74 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $142.50 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $141.65 | 2019-2020 | |
| Esperion Therapeutics, INC. | $127.86 | 2020-2025 | Nexletol |
| Axsome Therapeutics, INC. | $103.37 | 2023-2024 | Auvelity |
| Arbor Pharmaceuticals, INC. | $75.84 | 2019-2020 | |
| Amarin Pharma, INC. | $67.85 | 2019-2022 | |
| Antares Pharma, INC. | $66.02 | 2023 | Nocdurna, Tlando, Xyosted |
| Genentech USA, INC. | $62.53 | 2019-2020 | |
| Exact Sciences Corporation | $39.26 | 2023-2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $35.37 | 2022 | |
| Halozyme INC | $30.36 | 2023 | |
| Strongbridge US INC. | $23.99 | 2019-2020 | |
| Dexcom, INC. | $20.04 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $17.49 | 2022 | |
| Circassia INC. | $16.88 | 2019 | |
| Zyla Life Sciences, INC. | $16.18 | 2019 | |
| Astellas Pharma US INC | $16.03 | 2019 | |
| Currax Pharmaceuticals LLC | $15.12 | 2025 | Contrave |
| Teva Pharmaceuticals USA, INC. | $15.04 | 2019 | |
| Horizon Therapeutics Plc | $14.51 | 2020 | |
| Clarus Therapeutics INC. | $8.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Bocanegra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.